Edwards Lifesciences (NYSE: EW) CVP reports 146.3127-share stock sale

Rhea-AI Filing Summary

Edwards Lifesciences Corp executive Wayne Markowitz, CVP, JAPAC, reported selling 146.3127 shares of Common Stock on July 30, 2026, in a sale described as an open-market or private transaction at $86.0338 per share. After this sale, he directly holds 21533.5581 shares. The transaction was not designated as pursuant to a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Seller: 146.3127 shares

Net Sell 1 txn

Insider Markowitz Wayne

Role CVP, JAPAC

Sold 146.3127 shs ($13K)

Type	Security	Shares	Price	Value
Sale	Common Stock	146.3127	$86.0338	$13K

Holdings After Transaction: Common Stock — 21,533.5581 shares (Direct)

Key Figures

Shares sold: 146.3127 shares Sale price per share: $86.0338 Shares held after transaction: 21533.5581 shares +1 more

4 metrics

Shares sold 146.3127 shares Common Stock sale on July 30, 2026

Sale price per share $86.0338 Price for the 146.3127-share Common Stock sale

Shares held after transaction 21533.5581 shares Direct Common Stock ownership following the sale

Net buy/sell direction -146.3127 shares transactionSummary netBuySellShares reported as net-sell

Key Terms

beneficial ownership, Common Stock, open market or private transaction

3 terms

beneficial ownership regulatory

"This Form 4 reflects changes in beneficial ownership only"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Common Stock financial

"security title reported as Common Stock for the transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open market or private transaction financial

"transaction code description states Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/30/2026 - 05:31 PM Accepted by SEC EDGAR 07/30/2026 - 05:30 PM Learn about SEC filing dates

FAQ

What insider sale did Edwards Lifesciences (EW) report for Wayne Markowitz?

Edwards Lifesciences reported that CVP, JAPAC Wayne Markowitz sold 146.3127 shares of Common Stock. The sale occurred in an open-market or private transaction at $86.0338 per share, and he now directly holds 21533.5581 shares afterward.

On what date did the Edwards Lifesciences (EW) insider transaction take place?

The reported transaction for Edwards Lifesciences insider Wayne Markowitz occurred on July 30, 2026. He sold 146.3127 shares of Common Stock at $86.0338 per share in an open-market or private transaction and retained direct ownership of 21533.5581 shares.

How many Edwards Lifesciences (EW) shares does Wayne Markowitz hold after the sale?

Following the reported sale, Wayne Markowitz directly holds 21533.5581 shares of Edwards Lifesciences Common Stock. Before this filing he sold 146.3127 shares at $86.0338 per share in an open-market or private transaction, as reflected in his Form 4.

Was the Edwards Lifesciences (EW) insider trade under a Rule 10b5-1 plan?

The filing indicates the trade was not designated as being under a Rule 10b5-1 trading plan. The document-level Rule 10b5-1 checkbox was left unchecked, so the 146.3127-share sale appears outside an affirmed pre-arranged trading arrangement.

What price did the Edwards Lifesciences (EW) insider receive per share?

Wayne Markowitz’s reported sale of Edwards Lifesciences Common Stock was executed at $86.0338 per share. The transaction involved 146.3127 shares in an open-market or private transaction, after which his direct holdings totaled 21533.5581 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Markowitz Wayne

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, JAPAC

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/30/2026		S		146.3127	D	$86.0338	21,533.5581	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)